

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

عَلَيْكَ يَا اللَّهُ
مَنْ عَصَى
فِي عِلْمِهِ
وَمَنْ عَصَى
فِي غَلْمِهِ
وَمَنْ عَصَى
فِي سَلْمِهِ
وَمَنْ عَصَى
فِي حَلْمِهِ
وَمَنْ عَصَى
فِي نَلْمِهِ
وَمَنْ عَصَى
فِي تَلْمِهِ
وَمَنْ عَصَى
فِي جَلْمِهِ
وَمَنْ عَصَى
فِي دَلْمِهِ
وَمَنْ عَصَى
فِي ذَلْمِهِ
وَمَنْ عَصَى
فِي زَلْمِهِ
وَمَنْ عَصَى
فِي سَلْمِهِ
وَمَنْ عَصَى
فِي حَلْمِهِ
وَمَنْ عَصَى
فِي نَلْمِهِ
وَمَنْ عَصَى
فِي تَلْمِهِ
وَمَنْ عَصَى
فِي جَلْمِهِ
وَمَنْ عَصَى
فِي دَلْمِهِ
وَمَنْ عَصَى
فِي ذَلْمِهِ
وَمَنْ عَصَى
فِي زَلْمِهِ

ACKNOWLEDGEMENT

*Before all, thanks to ALLAH
who gave me the strength and patience to fulfil this work,*

I would like to express my gratitude to Prof. Dr. Samia Abd EL-Monem Ebied Professor of Applied Medical Chemistry, Applied Medical Chemistry Department, Medical Research Institute, University of Alexandria, for her precious advice, constructive guidance and valuable support during the course of the work,

I am deeply thankful and indebted to Prof. Dr. Hoda Abd EL-Hamid Nour Professor of Human Physiology, Human Physiology Department, Medical Research Institute, University of Alexandria, for her kind supervision, continuous guidance and support, constant encouragement and generous help from suggesting the idea of this research till the end of this work,

Words cannot express my gratitude to Dr. Samia Mohamed Elewa Assistant Professor of Human Physiology, Human Physiology Department, Medical Research Institute, University of Alexandria, for kindness, unlimited encouragement, and meticulous revision of the text, and great help during accomplishing this thesis.

I would like to thank Prof. Dr. Eman Salah EL-Din Khalil Professor of Internal Medicine, Internal Medicine Department, Medical Research Institute, University of Alexandria, for her sincere cooperation and valuable help.

I would like to thank all staff and members of the Applied Medical Chemistry Department and Human Physiology Department, for their enormous support and continuous encouragement.

Finally, I would like to express my deepest gratitude to my family and friends who supported me throughout this work,

LIST OF CONTENTS

Chapter	Page
ACKNOWLEDGMENT -----	i
LIST OF CONTENTS -----	ii
LIST OF TABLES -----	iii
LIST OF FIGURES -----	iv
LIST OF APPENDIX -----	viii
LIST OF ABBREVIATIONS -----	x
I. INTRODUCTION -----	1
II. AIM OF THE STUDY -----	30
III. SUBJECTS AND METHODS -----	31
IV. RESULTS -----	50
V. DISCUSSION -----	85
VI. SUMMARY & CONCLUSION -----	92
IX. REFERENCES -----	95
X. APPENDIX	
XI. PROTOCOL	
XII. ARABIC SUMMARY	

LIST OF TABLES

Table	Page
1. Diagnostic criteria for metabolic syndrome	4
2. The statistical analyses of age, body mass index (BMI), waist circumference (WC), waist/hip ratio (WHR), systolic and diastolic blood pressure in control and patients with metabolic syndrome	51
3. Effect of atorvastatin and atorvastatin+ vitamin E on blood pressure in metabolic syndrome patients (subgroups IIa& IIb), after 3 months of treatment	52
4. Statistical analyses of fasting serum glucose (FG), serum insulin (SI) and HOMA-IR in control and MS patients (subgroups IIa& IIb), before and after 3 months of treatment with either atorvastatin or atorvastatin+ vitamin E	54-55
5. Statistical analyses of high density lipoprotein (HDL), triglycerides (TG), total cholesterol (T.Cholest) and low density lipoprotein (LDL) in control and MS patients (subgroups IIa& IIb), before and after 3 months of treatment with either atorvastatin or atorvastatin+ vitamin E	59-60
6. Statistical analyses of serum 8-hydroxy-2'-deoxyguanosine (8-OHdG), serum malondialdehyde (MDA) and superoxide dismutase (SOD) in control and MS patients (subgroups IIa& IIb), before and after 3 months of treatment with either atorvastatin or atorvastatin+ vitamin E	64-65
7. Correlations of serum (8-OHdG), (MDA) levels and SOD activity with clinical and biochemical parameters	69

LIST OF FIGURES

Figure		Page
1.	The HMG-CoA reductase pathway, which is blocked by statins via inhibiting the rate-limiting enzyme HMG-CoA reductase	11
2.	Statins block the pathway for synthesizing cholesterol in the liver	12
3.	Cellular sites of superoxide generation and its compartmentalization	15
4.	The active oxygen system: four single-electron reduction steps from molecular oxygen to water	16
5.	Superoxide generation within enzymatic oxidations as, e.g. in the biological degradation of purines	16
6.	Role of active oxygen species in inflammation	18
7.	Structures of various products formed from the C8-OH-adduct radical of guanine, which itself is formed by attack of $\cdot\text{OH}$ on the C8-position of guanine	20
8.	Vitamin E structures are shown. The methyl groups on the chromanol head determine whether the molecule is α -, β - or γ -, or δ -, while the tail determines whether the molecule is a tocopherol or a tocotrienol	24
9.	Standard curve of serum insulin	35
10.	Standard curve of serum 8-OHdG	43
11.	Standard curve of serum MDA	46
12.	Superoxide dismutase standard curve	49
13.	Bar chart representing the mean of fasting serum glucose levels (mg/dL) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	56
14.	Bar chart representing the mean of serum insulin levels ($\mu\text{IU/mL}$) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	56

Figure		Page
15.	Bar chart representing the mean of HOMA-IR levels in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	57
16.	Bar chart representing the mean of serum HDL levels (mg/dL) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	61
17.	Bar chart representing the mean of serum triglycerides levels (mg/dL) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	61
18.	Bar chart representing the mean of serum total-cholesterol levels (mg/dL) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	62
19.	Bar chart representing the mean of serum LDL levels (mg/dL) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	62
20.	Bar chart representing the mean of serum 8-OHdG levels (ng/mL) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	66
21.	Bar chart representing the mean of serum MDA levels (nmol/mL) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	66
22.	Bar chart representing the mean of serum SOD activity (U/mL) in control and both metabolic syndrome subgroups (IIa)& (IIb) before and after 3 months of treatment with atorvastatin or atorvastatin+ vitamin E	67
23.	Correlation of 8-OHdG with waist circumference	70
24.	Correlation of 8-OHdG with systolic blood pressure	70
25.	Correlation of 8-OHdG with diastolic blood pressure	71
26.	Correlation of 8-OHdG with fasting serum glucose	71
27.	Correlation of 8-OHdG with HOMA-IR	72
28.	Correlation of 8-OHdG with triglycerides	72

Figure		Page
29.	Correlation of 8-OHdG with total-cholesterol	73
30.	Correlation of 8-OHdG with LDL	73
31.	Correlation of 8-OHdG with malondialdehyde	74
32.	Correlation of 8-OHdG with HDL	74
33.	Correlation of 8-OHdG with SOD activity	75
34.	Correlation of malondialdehyde with waist circumference	75
35.	Correlation of malondialdehyde with systolic blood pressure	76
36.	Correlation of malondialdehyde with diastolic blood pressure	76
37.	Correlation of malondialdehyde with fasting serum glucose	77
38.	Correlation of malondialdehyde with HOMA-IR	77
39.	Correlation of malondialdehyde with triglycerides	78
40.	Correlation of malondialdehyde with total-cholesterol	78
41.	Correlation of malondialdehyde with LDL	79
42.	Correlation of malondialdehyde with HDL	79
43.	Correlation of malondialdehyde with SOD activity	80
44.	Correlation of SOD activity with waist circumference	80
45.	Correlation of SOD activity with waist systolic blood pressure	81
46.	Correlation of SOD activity with diastolic blood pressure	81
47.	Correlation of SOD activity with fasting serum glucose	82
48.	Correlation of SOD activity with HOMA-IR	82
49.	Correlation of SOD activity with triglycerides	83

Figure		Page
50.	Correlation of SOD activity with total-cholesterol	83
51.	Correlation of SOD activity with LDL	84
52.	Correlation of SOD activity with HDL	84

LIST OF APPENDIX

Table	Page
I Age (years), body mass index (kg/m ²), waist circumference (cm), waist-hip ratio (WHR), systolic and diastolic blood pressure (B.P) of normal control subjects.	1
II Age (years), body mass index (kg/m ²), waist circumference (cm), waist-hip ratio (WHR), systolic and diastolic blood pressure (B.P) of metabolic syndrome patients.	2
III Systolic and diastolic blood pressure (B.P) of metabolic syndrome subgroups (IIa)& (IIb) after treatment with either atorvastatin or (atorvastatin + vitamin E).	3
IV Fasting serum glucose (mg/dL), serum insulin (μIU/mL) and homeostasis model assessment-insulin resistance (HOMA-IR) of normal control subjects.	4
V Fasting serum glucose (mg/dL), serum insulin (μIU/mL) and homeostasis model assessment-insulin resistance (HOMA-IR) of metabolic syndrome subgroup (IIa) before and after treatment with atorvastatin.	5
VI Fasting serum glucose (mg/dL), serum insulin (μIU/mL) and homeostasis model assessment-insulin resistance (HOMA-IR) of metabolic syndrome subgroup (IIb) before and after treatment with atorvastatin + vitamin E.	6
VII High-density lipoprotein (HDL mg/dL), triglycerides (TG mg/dL), total cholesterol (mg/dL) and low-density lipoprotein (LDL mg/dL) of normal control subjects.	7
VIII High-density lipoprotein (HDL mg/dL), triglycerides (TG mg/dL), total cholesterol (mg/dL) and low-density lipoprotein (LDL mg/dL) of metabolic syndrome subgroup (IIa) before treatment with atorvastatin.	8
IX High-density lipoprotein (HDL mg/dL), triglycerides (TG mg/dL), total cholesterol (mg/dL) and low-density lipoprotein (LDL mg/dL) of metabolic syndrome subgroup (IIa) after treatment with atorvastatin.	9
X High-density lipoprotein (HDL mg/dL), triglycerides (TG mg/dL), total cholesterol (mg/dL) and low-density lipoprotein (LDL mg/dL) of metabolic syndrome subgroup (IIb) before treatment with atorvastatin + vitamin E.	10
Table	Page
XI High-density lipoprotein (HDL mg/dL), triglycerides (TG mg/dL), total cholesterol (mg/dL) and low-density lipoprotein (LDL mg/dL) of metabolic syndrome subgroup (IIb) after treatment with atorvastatin + vitamin E.	11
XII Serum 8-hydroxy-2'-deoxyguanosine (8-OHdG ng/mL), malondialdehyde (MDA nmol/mL) and superoxide dismutase (SOD unit/mL) of normal control subjects.	12

XIII	Serum 8-hydroxy-2'-deoxyguanosine (8-OHdG ng/mL), malondialdehyde (MDA nmol/mL) and superoxide dismutase (SOD unit/mL) of metabolic syndrome subgroup (IIa) before and after treatment with atorvastatin.	13
XIV	Serum 8-hydroxy-2'-deoxyguanosine (8-OHdG ng/mL), malondialdehyde (MDA nmol/mL) and superoxide dismutase (SOD unit/mL) of metabolic syndrome subgroup (IIb) before and after treatment with atorvastatin + vitamin E.	14

LIST OF ABBREVIATIONS

A	Angstrom
4-AAP	4-Aminoantipyrine
ACE	Angiotensin-converting enzyme
AHA	American Heart Association
Akt	Protein Kinase B
ALS	Amyotrophic lateral sclerosis
AMP	Adenosine monophosphate
AMPK	5'-Adenosine monophosphate-activated protein kinase
AngII	Angiotensin II
apo B	Apolipoprotein B
ASTEROID trial	A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden
ATP	Adenosine triphosphate
ATPIII	Adult Treatment Panel III
Biol	Biomolecules
BMI	Body mass index
B.P	Blood pressure
BSA	Bovine serum albumin
CHD	Coronary heart disease
CHF	Congestive heart failure
CRP	C-reactive protein
CVD	Cardiovascular disease
DASH	Dietary Approaches to Stop Hypertension
DOCA	Deoxycorticosterone acetate
EGIR	European Group for the Study of Insulin Resistance
ELISA	Enzyme-Linked Immunosorbent Assay
eNOS	Endothelial nitric oxide synthase
ETC	Electron transport chain
FAD	Flavin adenine dinucleotide
FAPy-G	2,6-Diamino-5-formamido-4-hydroxypyrimidine
FFA	Free fatty acid
FG	Fasting serum glucose
GK	Glycerol kinase
GPO	Glycerol phosphate oxidase
GSH	Glutathione
GSH/GSSG ratio	Reduced glutathione/oxidized glutathione ratio
HDL	High-density lipoprotein
HMG-CoA	3-Hydroxy-3-methyl-glutaryl coenzyme A

HMP-shunt	Hexose Monophosphate Shunt
4-HNE	4-Hydroxynonenal
H ₂ O ₂	Hydrogen peroxide
HOMA-IR	Homeostatic model assessment of insulin resistance
HOO [•]	Dioxygen radical
HRP	Horseradish peroxidase
Hyperapob	Hyperapobetalipoproteinemia
8-OHdG	8-hydroxy-2'-deoxyguanosine
IDF	International Diabetes Federation
IGT	Impaired Glucose Tolerance
IL-6	Interleukin-6
IR	Insulin resistance
IRS	Insulin receptor substrate
LDL	Low-density lipoprotein
MDA	Malondialdehyde
MetS	Metabolic syndrome
MI	Myocardial infarction
MnTBAP	Manganese (III) tetrakis (4-benzoic acid) porphyrin
MRI	Medical Research Institute
mtDNA	Mitochondrial deoxyribonucleic acid
NAC	N-Acetyl cysteine
NAD ⁺	Nicotinamide adenine dinucleotide
NADP ⁺	Nicotinamide adenine dinucleotide phosphate
NaOCl	Sodium hypochlorite
NCEP	National Cholesterol Education Program
NEFA	Non-esterified fatty acid
NHLBI	National Heart, Lung, and Blood Institute
NO	Nitric oxide
ns	Nanosecond
(O ₂ ^{•-})	Superoxide anion radical
OFR	Oxygen-free radicals
OH ⁻	Hydroxide ion
[•] OH	Hydroxyl radical
8-OHG	8-Hydroxyguanine
ONOO ⁻	Peroxynitrite
oxLDL	Oxidized LDL
8-oxo-dG	8-Oxo-7,8-dihydro-2'-deoxyguanosine
PMN	Polymorphonuclear leukocytes
PP	Pyrophosphate
PUFA	Polyunsaturated fatty acid

ROO•	Peroxyl radicals
ROOH	Alkyl hydroperoxides
ROS	Reactive oxygen species
SD	Standard deviation
SDS	Sodium dodecyl sulfate
SHR	Spontaneously hypertensive rat
SI	Serum insulin
SOD	Superoxide dismutase
TBA	Thiobarbituric Acid
TBARS	Thiobarbituric Acid Reactive Substances
T. Cholest	Total cholesterol
T2DM	Type 2 diabetes mellitus
TG	Triglycerides
TMB	Tetramethylbenzidine
TNF- α	Tumor necrosis factor-alpha
α -TTP	Alpha-tocopherol transfer protein
VLDL	Very low density lipoprotein
V	Volts
WC	Waist circumference
WHO	World Health Organization
WHR	Waist to hip ratio
XO or XOD	Xanthine oxidase